RECURRENT ACUTE LYMPHOBLASTIC LEUKEMIA
Clinical trials for RECURRENT ACUTE LYMPHOBLASTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT ACUTE LYMPHOBLASTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for RECURRENT ACUTE LYMPHOBLASTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental drug combo targets tough leukemias in early trial
Disease control OngoingThis early-stage study tests a drug called palbociclib, given alone or with other medicines (sorafenib, decitabine, or dexamethasone), in 32 adults whose leukemia has returned or not responded to prior therapy. The main goal is to find the safest dose and check for side effects. …
Matched conditions: RECURRENT ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 03:12 UTC
-
Promising new combo targets tough infant leukemia
Disease control OngoingThis study tests a new oral drug (revumenib) combined with chemotherapy in infants and young children up to 6 years old whose leukemia has returned or not responded to treatment. The leukemia must have a specific genetic change called KMT2A rearrangement. The goal is to see if th…
Matched conditions: RECURRENT ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Promising combo targets leukemia in older patients
Disease control OngoingThis study tests two drug combinations for adults aged 65 and older with acute lymphoblastic leukemia (ALL). One group gets blinatumomab plus standard chemotherapy; the other gets blinatumomab, dasatinib, and prednisone. The goal is to see if these combos help control the cancer …
Matched conditions: RECURRENT ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
Engineered immune cells take on tough leukemia
Disease control OngoingThis early-stage study tests a new cellular therapy for adults with high-risk acute lymphoblastic leukemia (ALL) that has come back or not responded to treatment. Researchers take a patient's own white blood cells, add a gene to help them recognize and attack cancer cells, and in…
Matched conditions: RECURRENT ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 12, 2026 13:43 UTC
-
Promising combo tackles Hard-to-Treat leukemia
Disease control OngoingThis study tests a combination of low-intensity chemotherapy, a targeted drug called ponatinib, and an immunotherapy called blinatumomab in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL), a fast-growing blood cancer. The goal is to see if this app…
Matched conditions: RECURRENT ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:46 UTC
-
New transplant timing strategy may tame High-Risk blood cancers
Disease control OngoingThis study tests a specific schedule of chemotherapy drugs (busulfan and fludarabine) followed by a donor stem cell transplant for people with high-risk blood cancers like leukemia and lymphoma. After the transplant, a drug called cyclophosphamide is given to help prevent the don…
Matched conditions: RECURRENT ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 08, 2026 12:04 UTC